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Tumor angiogenesis is a process which is traditionally regarded as the tumor’s response 
to low nutrient supply occurring under hypoxic conditions. However, hypoxia is not a 
pre-requisite for angiogenesis. The fact that even single tumor cells or small tumor cell 
aggregates are capable of attracting blood vessels reveals the early metastatic capability 
of tumor cells. This review sheds light on the hypoxia-independent mechanisms of tumor 
angiogenesis in melanoma.
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Angiogenesis in Melanoma
Melanomas originate from cutaneous or extracutaneous melanocytes. In case of cutaneous 
melanoma, 25–35% of the tumors are derived from pre-existing nevi, although the origin of the 
remaining tumors is unknown. The transformation of nevi to melanoma can be reconstructed by 
a well-described progression model (1). By various oncogenic or epigenetic events, nevi can be 
stimulated to develop into the radial growth phase (RGP). At this stage, the pre-malignant cells 
expand in horizontal direction with restriction to the epidermis. RGP melanomas are <0.75 mm 
thick. When excised at this early stage, patients have an excellent prognosis, as the RGP tumors 
are generally not able to metastasize, and angiogenesis does not occur. During the next step, the 
transition to the vertical growth phase (VGP), melanomas gain the ability to cross the basal layer of 
the epidermis and to invade the deeper dermal layers of the skin. VGP tumors, which are >0.75 mm 
in size, have the potential to metastasize and to induce angiogenic events. The “angiogenic switch”, 
describing the gain of the ability to induce numerous pro-angiogenic factors, is a characteristic 
feature of the transition from RGP to VGP melanomas (2), and the pro-angiogenic features are 
even more enhanced in melanoma metastases. Pro-angiogenic factors can already be secreted by 
RGP melanoma cells in vitro under appropriate conditions, such as the presence of fibroblasts (3). 
However, because of their epidermal location, they are not able to attract blood vessels. Overall, 
the process of tumor angiogenesis contributes to the initial events of melanoma development, but 
it is also important for the maintenance, progression, and further spreading of already metastasized 
melanomas.
The diffusion limit of oxygen between cell and blood vessel is ~100–200 μm (4). Consequently, 
in absence of nutrient supply by the blood, the tumor size is limited to 0.2–2 mm in diameter (5). 
Interestingly, observations from animal models of melanoma show that tumor angiogenesis can 
already occur when melanomas are clearly below this size limit. In order to enable the detection of 
pro-tumorigenic events at this small-size scale, transgenic fish models with blood vessel-specific 
expression of fluorescent proteins are a valuable tool. In a xenotransplant model performed 
in zebrafishes which express eGFP under the flk1 promoter (with flk1 encoding Vegfr-2), it 
was shown that 15–30 injected melanoma cells already elicit an angiogenic response (6). For 
their experiments, the authors used the strongly metastatic murine B16-F10 melanoma cells. 
May 2015 | Volume 5 | Article 1022
 Meierjohann Mechanisms of incipient tumor angiogenesis
Frontiers in Oncology | www.frontiersin.org
In our own laboratory, we investigated tumor angiogenesis in 
a genetic medaka fish melanoma model where the expression 
of a fish-specific oncogenic epidermal growth factor receptor 
(EGFR) leads to strong pro-tumorigenic signaling which is 
enhanced by autocrine loops (7, 8) and results in the malignant 
transformation of pigment cells and tumor development (9, 
10). This fish EGFR is termed Xiphophorus melanoma recep-
tor kinase (Xmrk) and was identified in naturally occurring 
melanoma of Xiphophorus fishes, the first described animal 
model for melanoma (11, 12). To visualize blood vessels, we 
used eGFP expression driven by the fli-1 promoter, with Fli1 
being a transcription factor strongly expressed in myeloid and 
endothelial cells. Strikingly, we observed that single melanoma 
cells had already the capacity to induce neoangiogenesis (13). 
These data are corroborated by earlier observations in a murine 
angiogenesis model of other tumor types based on dorsal skin-
fold window imaging. Using fluorescent HCT116 human colon 
carcinoma cells and 4T1 murine mammary carcinoma, Cao and 
colleagues observed that incipient tumor angiogenesis can occur 
independently from hypoxia (14). In line with the results from 
these animal models, an association of angiogenesis with small 
cutaneous melanomas <1 mm in diameter was already described 
>20  years ago (15). To better comprehend the early steps of 
melanomagenesis, the following sections aim at increasing the 
understanding of angiogenic processes which can occur before 
a critical tumor mass is reached.
In general, tumor angiogenesis is regarded as a result from intra-
tumoral hypoxia, which leads to the activation of hypoxia-inducible 
factor-1 (HIF1), one of the best-studied angiogenesis-related 
transcription factors. HIF1 is composed of the subunits HIF1α 
and HIF1β. HIF1β [also called aryl hydrocarbon receptor nuclear 
translocator (ARNT)] is constitutively expressed, whereas the 
abundance of HIF1α is strictly regulated and thereby determines 
the activity of the dimeric transcription factor. Under normoxic 
conditions, human HIF1α is hydroxylated on Pro402 and Pro564 
by prolyl-4 hydroxylases (PDHs), thus leading to the recognition 
by the ubiquitin ligase component von Hippel Lindau protein 
(pVHL) and proteasomal degradation (16). PDHs exhibit an abso-
lute requirement for oxygen, Fe2+ and α-ketoglutarate, the latter 
being a co-substrate for the enzymes. When pO2 is low, prolyl 
hydroxylation of HIF1α is suppressed, and the protein is stabilized 
(17). HIF1 is a potent inducer of pro-angiogenic factors includ-
ing vascular endothelial growth factor (VEGF), angiopoietin-2, 
matrix metalloprotease 14 (MMP14), and angiogenin (18–20). 
Notably, next to angiogenesis, HIF1 regulates a large number of 
genes involved in invasion, differentiation, and metabolism as 
well as protection from apoptosis in melanoma. These processes 
are not in the scope of this review and are summarized elsewhere 
(21, 22).
Although HIF1α is already expressed in nevi, most likely as a 
result from the mild hypoxic conditions, which occur in skin (23), 
HIF1 expression and activity is increased in melanoma and cor-
relates with decreased differentiation and VEGF expression (22, 24, 
25). In a genetic mouse melanoma model driven by melanocyte-
specific Braf  V600E induction and Pten depletion, HIF1α is required 
for angiogenesis and metastasis without affecting primary tumor 
formation (26).
Hypoxia-independent Regulation of HiF1α
In addition to the well-described hypoxia-dependent regulation 
mechanism, there are several hypoxia-independent processes, 
which can lead to the stabilization of HIF1α. These seem to play 
an important role in melanoma, where HIF1α is constitutively 
expressed – a fact, which is not necessarily due to the prevalence 
of hypoxic conditions. As an example, protein expression of 
HIF1α is strong in melanoma cells predominantly expressing 
HIF1α-785, a splice isoform lacking a crucial part of the oxygen-
dependent degradation domain (27). Under normoxic conditions, 
HIF1α can be stabilized by various growth factors, cytokines and 
oncogenes, as shown for BRAFV600E in melanoma (28). Next to 
BRAF/MEK/ERK signaling, the PI3K pathway is involved in the 
increase of HIF1α protein levels, e.g., via the PI3K downstream 
component 70  kDa ribosomal S6 kinase 1 (p70S6K1) (29–31). 
The PI3K pathway is frequently activated in melanomas because 
of deletions or inactivating mutations in the phosphatase PTEN or 
activation mechanisms, which encompass upstream components. 
In addition, endothelin-1 (ET-1)-dependent activation of the 
PI3K pathway could be directly linked to HIF1α stability under 
normoxic conditions in melanoma cells. Here, RNA and protein 
levels of the prolyl hydroxylase PHD2 were reduced in response 
to ET-1-dependent PI3K activation, and this was accompanied 
by increases in HIF1α (32). HIF1α accumulation can also take 
place in presence of enhanced reactive oxygen species (ROS) and 
NF-κB in melanoma (33, 34), both being commonly deregulated 
in this cancer type (35, 36).
The melanocytic master regulator and melanoma oncogene 
microphthalmia-associated transcription factor (MITF) is another 
important melanoma player. It was first described as a lineage-
determining factor in melanocytes, which regulates the expression 
of genes involved in pigment production (37, 38). Nowadays, 
many more target genes of MITF are identified [reviewed in Ref. 
(39)], including HIF1A, which is regulated by MITF in a hypoxia-
independent manner (40, 41). Notably, MITF cannot generally 
be considered as oncogenic, as its effects seem to depend on the 
expression level. While the entire depletion of MITF in melanoma 
cells can lead to cell cycle arrest and senescence, low MITF activity 
is associated with stem cell-like properties and invasiveness (42, 
43). High MITF activity, however, promotes differentiation and 
exit from the cell cycle (44, 45). Different MITF levels lead to the 
targeting of different gene sets, which explains the observed con-
centration dependent effects. Next to the MITF expression level, 
protein modifications exhibit another measure to alter target gene 
expression. It could be demonstrated that the inheritance of mutant 
MITFE318K predisposes to familial melanoma. This mutant exhibits 
defective SUMOylation, which results in an altered transcription 
of target gene subtypes in comparison to wildtype MITF. Among 
others, MITFE318K shows enhanced binding to the HIF1α promoter 
and results in enhanced transcriptional activity of HIF1α (46).
However, HIF1α is not necessarily required for tumor angio-
genesis. Early studies performed with RAS-transformed MEFs 
derived from Hif1a-/- mice showed that oncogenic HRAS is 
able to induce full tumor vascularization in the xenotransplants 
(47). Although HRAS plays a negligible role in melanoma, 
NRAS, which is activated in 15–20% of cutaneous melanoma, 
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has strong functional overlap with the other RAS isoforms. 
These data are corroborated by the observation that mutant 
NRAS cooperates with the scaffold protein GAB2, which is often 
co-expressed with oncogenic NRAS, to increase angiogenesis 
and VEGF transcription in hypoxic and normoxic conditions 
in melanoma (48). By stimulating the expression of several 
matrix metalloproteases and urokinase plasminogen activator, 
RAS isoforms can furthermore contribute to the release and 
maturation of VEGF (49).
Alternative inducers of  
Hypoxia-independent Angiogenesis
Reactive Oxygen Species
Several inducers of cellular stress have the capacity to affect tumo-
rigenic behavior by altering proliferative or metastasis-relevant 
effects.
As an example, reactive oxygen species (ROS) were reported 
to promote proliferation, migration and angiogenesis, if they are 
produced at sublethal concentrations. In endothelial cells, ROS, 
induced by NADPH oxidases, play an important role for prolifera-
tion, migration, and consequently the whole angiogenic sprouting 
process (50, 51). VEGFA and angiopoietin-1 belong to the factors, 
which activate endothelial NADPH oxidase activation (52–54). 
Consequently, tumors which secrete VEGFA or angiopoietin-1 
lead to the production of pro-angiogenic ROS in the endothelial 
target cells. In addition, endogenously produced ROS inside the 
tumor trigger production and secretion of pro-angiogenic factors. 
Receptor tyrosine kinases, such as EGFR, are potent sources of 
intracellular ROS. The oncogenic fish EGFR Xmrk triggers the 
production of ROS in a manner, which includes the activation of 
NADPH oxidases. A high receptor density correlates positively 
with ROS levels and causes cellular senescence in melanocytes 
in vitro (55, 56). In developed melanomas of the Xmrk-expressing 
Xiphophorus or medaka fishes, several countermeasures are active 
to prevent the accumulation of toxic ROS levels [Ref. (57) and 
unpublished observations]. Still, slightly elevated ROS are required 
for hypoxia-independent angiogenesis, which can even be caused 
by single transformed cells (13). This was mediated by ROS-
dependent activation of NF-κB, which led to the production of the 
pro-angiogenic factor angiogenin. Therefore, an early activation 
of NF-κB constitutes an exceptionally efficient angiogenesis trig-
ger. The NF-κB subunit p50 correlates with a poor prognosis and 
reduced 5-year survival in melanoma and has been early implicated 
in angiogenesis (58, 59). Next to angiogenin and VEGF, IL-6 is 
another prominent example for a pro-angiogenic factor induced 
by NF-κB in melanoma (60).
NF-κB can be activated by several pathways in melanoma. It 
was described that the integrin-linked kinase ILK, which correlates 
with melanoma progression and invasion, enhances the activity 
of NF-κB and thereby leads to the secretion of IL-6 and VEGF in 
melanoma cells. As a consequence, microvessel formation is induced 
(61). In addition, NF-κB is suppressed by the breast cancer metas-
tasis suppressor 1 (BRMS1), which effectively blocks angiogenic 
events. In melanoma, BRMS1 is decreased, and low expression is 
significantly correlated to reduced 5-year survival (62).
The ROS-induced DNA damage leads to the activation of 
DNA damage pathways. The serine/threonine protein kinase 
ataxia-telangiectasia mutated (ATM) is an important DNA damage 
sensor and inducer of checkpoints, which helps to halt the cell 
cycle to allow for DNA repair. P53, histone 2AX, and checkpoint 
homolog CHK2 belong to the protein targets of ATM. They are 
activated by phosphorylation, thus enabling them to fulfill their 
tumor-suppressive functions. However, ATM can also exert pro-
angiogenic and tumor-promoting effects. In transplanted B16 
melanomas, ROS led to the activation of endothelial ATM, which 
specifically resulted in tumor angiogenesis (63).
Furthermore, the nuclear factor (erythroid-derived 2)-like 2 
(NRF2) is a transcription factor, which is strictly controlled by 
ROS levels. When cellular ROS stress is low, NRF2 is kept in the 
cytoplasm by its interaction partner, Kelch like-ECH-Associated 
Protein 1 (KEAP1), becomes ubiquitinated, and is quickly 
degraded. Under conditions of high reactive oxygen stress, criti-
cal cysteine residues of KEAP1 are disrupted, allowing for NRF2 
stabilization and translocation to the nucleus. Here, NRF2 induces 
the transcription of genes involved in antioxidant pathways includ-
ing the glutathione and thioredoxin pathways (64).
NRF2 is also indirectly involved in increasing the levels of 
VEGFA in an activating transcription factor 4 (ATF4) or HIF1α-
dependent manner (65–69).
Although hypoxia and elevated ROS levels seem to contradict 
each other at first sight, they are strongly intertwined, and in solid 
tumors it is hardly possible to clearly distinguish between hypoxia-
induced and ROS-induced angiogenesis. ROS are paradoxically 
generated under hypoxic conditions. This is presumably caused by 
reduced electron flux through the electron transport chain, which 
might lead to a prolonged lifetime of the semiquinone radical. This, 
in turn, might favor the generation of superoxide from molecular 
oxygen (70). The thus generated ROS can also contribute to HIF1α 
stability. Recently, Calvani and colleagues described that HIF1α 
enhances its own stability via a bicyclic ROS-mediated positive 
feedback loop in melanoma cells: during hypoxia, ROS are gener-
ated in the mitochondrial electron transport chain and elevate 
HIF1α stability, thereby leading to enhanced VEGFA expression. 
The following autocrine stimulation of VEGFR2 is further sup-
porting HIF1α stabilization, presumably by a mechanism involving 
NADPH oxidase dependent ROS (71).
In addition to inducing angiogenic sprouting from existing 
blood vessels, some metastatic tumors are capable of vascular 
mimikry (VM). This observation was first made in aggressive 
melanomas (72) and was only later detected in other tumor entities. 
VM describes the transdifferentiation to an endothelial phenotype, 
thus allowing the formation of vessel-like structures and helping 
to maintain nutrient supply in the tumor. These structures can 
connect with the capillary network and are associated with poor 
prognosis (73). ROS seem to be important promoters of VM, as 
several ROS scavengers including N-acetylcysteine and resveratol 
strongly inhibit the formation of capillary structures in melanoma 
cells in vitro and, as demonstrated for resveratol, in vivo (74).
In addition to endogenous ROS production, cells of the tumor 
niche can generate various ROS species and thereby contribute 
to tumor angiogenesis. As an example, tumor-promoting mac-
rophages are recruited to tumor cells by chemotactic factors 
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including CCL2, VEGFA, and M-CSF. Macrophages are effective 
producers of ROS and reactive nitrogen species (RNS) (such as 
nitric oxide) and thus help to create a pro-inflammatory environ-
ment, which supports tumor angiogenesis (75).
Consistent with the role of ROS in melanoma progression 
and angiogenesis, the supplementation with antioxidants can 
prevent or alleviate the development of metastases. Selenium 
is an essential trace element needed for the generation of 
selenocysteine, an amino acid with high redox activity, which 
is present at catalytically active sites of various antioxidant 
enzymes. Selenite supplementation decreases the ROS load in 
cancer cells, with corresponding inhibitory effects on HIF1α, 
VEGF, and lung metastasis of murine melanoma cells (76, 77). 
The antioxidant N-acetylcysteine has similar anti-angiogenic as 
well as anti-metastatic effects (78). Owing to their numerous 
effects on signal transduction in and between cells, ROS and RNS 
are among the most efficient multi-functional angiogenesis and 
metastasis modulators.
Unfolded Protein Response
Next to harboring the equipment for protein synthesis and matura-
tion, the endoplasmatic reticulum (ER) is a crucial stress sensor 
and a regulator of cellular homeostasis. Nutrient starvation as well 
as nutrient excess are received as ER stress and are translated into 
different cellular responses which protect the cellular or tissue integ-
rity. Owing to their high proliferation rate and altered metabolism, 
the demand for protein production in the ER is very high in tumor 
cells, thus generating conditions, which permit ER stress (79). The 
unfolded protein response (UPR) is a mechanism activated in the ER 
by the accumulation of mis- or unfolded protein, which can occur in 
fast growing tumors or under conditions of hypoxia, low pH, or low 
nutrient supply. The UPR generally serves the cellular integrity by 
enabling ER homeostasis under ER stress and is composed of three 
pathways, which stimulate protein folding, protein degradation, and 
the transient inhibition of protein synthesis (80). UPR activity also 
plays a role during tumor development, and the angiogenic switch 
was reported to be induced by the PERK/ATF4 pathway in a HIF1α 
independent manner (81). UPR activation is able to enhance the 
transcription of pro-angiogenic factors including VEGFA, FGF2, 
angiogenin, and angiopoietin-2 and to downregulate the expression 
of several angiogenesis inhibitors (81, 82). In melanoma, activation 
of the UPR component GRP78 is correlated with metastases and 
shorter survival (83).
Notably, the UPR can also be considered as a part of the ROS 
network: On the one hand, ROS can trigger the UPR and on the 
other hand, all three UPR pathways are implicated in the genera-
tion of ROS (79).
PGC-1α
Observations from neoangiogenic processes of normal healthy 
tissues also provide valuable information, which can be relevant 
for tumor biology. In adipose tissue, hypoxia-independent angio-
genesis during cold acclimation is regulated by mitochondrial 
proteins (84). Adipose tissue is prone to constant changes of size 
and volume and is accompanied by corresponding adaptations 
of tissue vascularization. When the organism is exposed to 
cold temperature, expression of the mitochondrial biogenesis 
regulator PGC-1α is induced. PGC-1α is able to activate VEGFA 
expression at the transcriptional level in an HIF1α-independent 
manner (85). Consequently, several pro-angiogenic factors 
including VEGFA are produced hypoxia independently by cold 
acclimation, leading to VEGFR2-dependent angiogenesis of the 
adipose tissue (84). A high expression of PGC-1α is found in 
~10% of melanomas and is associated with poor overall survival 
(86). The link between PGC-1α, VEGF, and angiogenesis has 
not been investigated in melanoma to date. It would be interest-
ing to analyze whether the survival disadvantage of patients 
with highly PGC-1α expressing melanoma is related to an 
increased tumor angiogenesis. Of note, BRAF inhibitors, which 
are routinely used in the clinic for the treatment of patients with 
BRAFV600E positive melanomas, have been reported to suppress 
PGC-1α expression (87). Whether PGC-1α is re-expressed in 
recurrent melanoma and contributes to the fast progression after 
BRAF inhibitor resistance development is currently unknown. 
Table 1 summarizes the mentioned hypoxia-independent pro-
angiogenic mechanisms in melanoma.
Concluding Remarks
Pro-angiogenic events caused by hypoxia-independent cues 
allow incipient tumors to recruit blood vessels even before a 
critical tumor mass is reached. This provides the first entry 
point into the vasculature and might enable small tumor cell 
colonies, which produce the appropriate signals, to metastasize. 
Genomic information from several melanomas from different 
stages in the same patients lead to the conclusion that the first 
step of metastasis can occur very early during tumor formation 
(88, 89). The underlying reasons are most likely found in the 
TABle 1 | list of the hypoxia-independent pro-angiogenic mechanisms 
with relevance to melanoma.
Angiogenesis 
inducer
Pro-angiogenic effect Reference
BRAFV600E HIF1A expression (28)
PI3 kinase Increase of HIF1 α protein (29–31)
ET-1 Increase of HIF1 α protein (32)
ROS Increase of HIF1 α protein (34, 71)
NF-κB Increase of HIF 1 α protein (33, 34)
MITF HIF1A expression (40, 46)
NRAS (with GAB2) VEGFA expression (48)
ILK NF-κB activation, IL-6, and VEGFA 
expression
(61)
Reduction of 
BRMS1
Increased NF-κB activity (62)
ROS NF-κB activation, ANG expression (13)
ROS ATM induction (63)
NRF2 VEGFA expression (ATF4- or 
HIF1α-dependent)
(65–69)
UPR VEGFA, FGF2, ANG, ANGPT2 expression (81, 82)
PGC-1α VEGFA expression (84)
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incipient tumor-initiated angiogenesis of blood and lymph 
vessels. Although the colonization at distant sites is also deter-
mined by additional factors, the knowledge of the first possible 
metastatic events is invaluable to understand the timing of 
melanoma development.
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